X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Holly Campbell

Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.

Recent Posts

OptumRX: Sharing rebates with patients is “worth it”

By Holly Campbell  |    March 18, 2019
PhRMA has long advocated for sharing the $166 billion in rebates and discounts given by biopharmaceutical companies to the government, insurers, and pharmacy benefit managers (PBMs) with patients...   Read More

GOBOLDLY ad showcases need to foster America’s leadership in medical innovation

By Holly Campbell  |    February 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released Breakthrough, the latest chapter of GOBOLDLY advertising showcasing the extraordinary medical breakthroughs being...   Read More

What you need to know about the new NHE health spending projections

By Holly Campbell  |    February 22, 2019
This week, National Health Expenditure (NHE) data released by the Centers for Medicare & Medicaid Services (CMS) projected retail medicine spending grew 3.3 percent in 2018. Each year, CMS...   Read More

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

New IQVIA data show medicine prices grew just 1.5 percent in 2018

By Holly Campbell  |    January 29, 2019
Last year, the U.S. Food and Drug Administration approved a record of 59 novel new medicines. During this incredible era of innovation, medicine prices grew just 1.5 percent in 2018, after...   Read More

Health Affairs study misses the mark on medicine costs

By Holly Campbell  |    January 28, 2019
A recent study published in Health Affairs concludes that list price inflation for existing brand medicines is a key driver of rising medicine spending. However, by failing to account for the...   Read More

New government data show medicine price growth continues to decline

By Holly Campbell  |    January 18, 2019
Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.   Read More

New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

By Holly Campbell  |    January 18, 2019
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not...   Read More

10 things you should know about medicine spending and costs

By Holly Campbell  |    January 2, 2019
Updated on 06/19/2019 Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that...   Read More

Six key facts about the market for insulins

By Holly Campbell  |    December 17, 2018
The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates